Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease

Authors not listed

Central Hospital, Nancy, France · 2024

Abstract

Alzheimer's disease (AD) is the leading cause of dementia in France. It is a multifactorial pathology, combining genetic and environmental risk factors. Homocysteine, a sulfur-containing amino acid belonging to the methionine-monocarbon cycle, has frequently been found at high levels in neurodegenerative diseases, and in AD in particular. It has been shown on human brain sections that the interaction of homocysteine with tau and MAP1, two key AD proteins, was significantly higher in AD patients than in controls, and corresponded to an N-homocysteinylation type interaction. This is a prospective study, the main objective of which is to compare MAP1 N-homocysteinylation levels in fibroblasts from individuals with AD versus disease-free cell lines.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2024). Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease. <em>Central Hospital, Nancy, France</em>. https://clinicaltrials.gov/study/NCT06168955
Vancouver
Anonymous. Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease. Central Hospital, Nancy, France. 2024.
BibTeX
@misc{anon2024Studyo, title = {Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease}, author = {Anonymous}, journal = {Central Hospital, Nancy, France}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings